drugset / Trial / NCT00543959

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

NCT00543959

Phase 2 Terminated 346 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.

Timeline

Start
2006-06
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0533 Small molecule 5 mg
Subject MK0533 Small molecule 15 mg
Subject MK0533 Small molecule 30 mg
Comparator Pioglitazone Small molecule 45 mg